Leadership: Page 7
-
Getty Images
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
A rebound in M&A seems to be on the docket, but analysts are warning companies to be intentional about where they go with it.
By Michael Gibney • March 19, 2024 -
Kevin Dietsch via Getty Images
5 Big Pharma CEOs who saw major pay bumps in 2023
Pharma’s recent wins have led to pay windfalls for several company leaders.
By Amy Baxter • March 18, 2024 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Permission granted by Aily Labs
Ex-Novartis exec sets out to create ‘Apple of AI’
Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.
By Kelly Bilodeau • March 18, 2024 -
Getty Images
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.
By Michael Gibney • March 12, 2024 -
Permission granted by Tarsus Pharmaceuticals
Q&AInto the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
By Meagan Parrish • March 8, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx ALS drug fails crucial study, putting company’s future in doubt
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
By Jacob Bell • Updated March 8, 2024 -
Permission granted by Natalie Ferguson/American Gene Technologies
ProfileHIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.
By Michael Gibney • March 5, 2024 -
Getty Images
Q&ABiogen partner NeuroSense seeks a role in the ALS revolution
Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.
By Michael Gibney • Feb. 29, 2024 -
Permission granted by Lindus Health
Can a top scientist and Moderna co-founder change the CRO game?
From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.
By Michael Gibney • Feb. 28, 2024 -
Getty Images
A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain
How research companies can shift strategies to attract and retain the staff that keeps trials humming along.
By Kelly Bilodeau • Feb. 28, 2024 -
Getty Images
BioMarin preaches patience amid slow sales for hemophilia gene therapy
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
By Ben Fidler • Feb. 23, 2024 -
Maddie Meyer via Getty Images
Q&AFor Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test
Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.
By Amy Baxter • Feb. 23, 2024 -
Getty Images
AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma
Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.
By Michael Gibney • Feb. 22, 2024 -
Chip Somodevilla/Getty Images via Getty Images
Biden or Trump: How deeply will 2024’s election outcome impact pharma?
The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.
By Michael Gibney • Feb. 20, 2024 -
Getty Images
Pharma CFOs need R&D vigilance in tough economic times
Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.
By Amy Baxter • Feb. 16, 2024 -
Courtesy of Biogen
The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround
A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.
By Michael Gibney • Feb. 15, 2024 -
Permission granted by Pfizer
‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity
The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.
By Michael Gibney • Feb. 14, 2024 -
Win McNamee via Getty Images
FDA inches closer to defining its regulatory role in AI
Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.
By Amy Baxter • Feb. 12, 2024 -
Getty Images
Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps
While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.
By Michael Gibney • Feb. 8, 2024 -
Permission granted by Mural Oncology
Q&AWhy a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care
With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.
By Alexandra Pecci • Feb. 6, 2024 -
Getty Images
Vaxxinity is brewing up meds for a spacefaring future
The biotech’s bone- and muscle-building treatments could someday help humans reach other planets.
By Kelly Bilodeau • Feb. 5, 2024 -
Getty Images
Merck keeps deal focus with Keytruda patent cliff on horizon
The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.
By Ned Pagliarulo • Feb. 1, 2024 -
Drew Angerer via Getty Images
Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?
In the first earnings call since the $43 billion Seagen deal closed, CEO Albert Bourla stressed that Pfizer is all in on the promise of ADCs to make up for COVID losses.
By Michael Gibney • Feb. 1, 2024 -
Permission granted by City of Hope
Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?
The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.
By Michael Gibney • Jan. 31, 2024 -
Permission granted by Amylyx
Q&A‘1 plus 1 equals 3’ — the co-CEO model in pharma
Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.
By Meagan Parrish • Jan. 26, 2024
Previous
